Inovio Pharmaceuticals Inc (NASDAQ:INO) announced that preclinical testing of its synthetic vaccine for the Zika virus induced robust and durable immune responses, demonstrating the potential for a SynCon® vaccine to prevent and treat infections from this harmful pathogen. Health authorities have observed neurological and autoimmune complications potentially associated with Zika virus, including microcephaly in newborns and Guillain-Barre syndrome. Inovio is developing its Zika vaccine with GeneOne Life Sciences (KSE:011000) and academic collaborators.

Dr. J. Joseph Kim, Inovio’s President and CEO, said, “Using our SynCon® technology we rapidly generated a synthetic vaccine candidate that shows promise as a preventive and treatment. With robust antibody and killer T cell responses generated by our vaccine in mice, we will next test the vaccine in non-human primates and initiate clinical product manufacturing. We plan to initiate phase I human testing of our Zika vaccine before the end of 2016.”

In this pre-clinical study, DNA vaccine constructs targeting multiple Zika virus antigens were synthetically generated using Inovio’s SynCon vaccine technology. These SynCon constructs were administered using Inovio’s CELLECTRA® electroporation delivery technology. Inovio’s Zika DNA vaccine resulted in seroconversion, or the development of detectable specific antibodies in the blood, in all vaccinated mice. Researchers also observed that vaccination generated robust and broad T cell responses as analyzed by the standardized T cell ELISPOT assay. These findings are vital given the potential importance of neutralizing antibodies in preventing infection and the role T cells play in clearing infection by killing cells that harbor the virus.

Zika virus belongs to the flavivirus family, which includes dengue and West Nile virus (WNV). Inovio previously published robust immunogenicity and challenge protection data for its SynCon dengue and WNV vaccine candidates. Inovio’s Zika program builds on its extensive previous preclinical development experience with flavivirus-related vaccines. (Original Source)

Shares of Inovio are up nearly 8% in pre-market trading. INO has a 1-year high of $10.83 and a 1-year low of $4.50. The stock’s 50-day moving average is $5.88 and its 200-day moving average is $6.60.

On the ratings front, Inovio has been the subject of a number of recent research reports. In a report issued on February 12, Maxim Group analyst Jason McCarthy reiterated a Buy rating on INO, with a price target of $14, which represents a potential upside of 113.1% from where the stock is currently trading. Separately, on January 29, H.C. Wainwright’s Yi Chen reiterated a Buy rating on the stock and has a price target of $17.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason McCarthy and Yi Chen have a total average return of -22.5% and -26.7% respectively. McCarthy has a success rate of 20.0% and is ranked #3554 out of 3610 analysts, while Chen has a success rate of 21.7% and is ranked #3484.

Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.